The men were randomly given a fixed combination of saw palmetto extract and stinging nettle root or the 5-alpha-reductase
inhibitor Proscar (finasteride).
Finasteride, which targets type 2 5-alpha-reductase
, reduces the levels of dihydrotestosterone within hair follicles, which can improve HS symptoms, she said.
A team led by Edinburgh University and University College London studied about 55,000 men in the UK, who had been prescribed 5-alpha-reductase
inhibitors over an 11-year period.
At the time, scientists and doctors knew that prostate cancers were hormonally sensitive, and finasteride, the first 5-alpha-reductase
inhibitor, which targets and blocks the action of androgens like testosterone, became available to test.
One such critical enzyme is 5-alpha-reductase
(5[alpha]-R): When its effects go awry, the consequences can be dramatic--altering the body via sex hormones and nervous system function through its neurosteroids.
In the ventral prostate, the stromal compartment presents cells (fibroblasts, myofibroblasts, vascular endothelial cells, and smooth muscle cells), which secrete growth factors, produce extracellular matrix, and express androgen receptors, estrogen receptors, adrenergic receptors and 5-alpha-reductase
(Berry et al., 2008).
inhibitors (5-ARIs) are a totally different kind of drug, which shrink the glandular tissue of the prostate, reducing its bulk to eventually reduce constriction by the prostate as well.
So they concluded that despite the benefits of anti-androgens for hirsute women are limited, they are still good candidates for a drug-dependent treatment plan.12 It is believed that in hirsute women, higher levels of 5-alpha-reductase
can be found in skin, so it gave us the clue to use topical finasteride in order to lower this enzyme's activity in skin and as a consequence reduce unwanted hair in the affected area, especially on the face and chin.
Dihydrotestosterone (DHT) is a male hormone produced from testosterone by an enzyme called 5-alpha-reductase
. Dihydrotestosterone is linked with both the growth of prostate cells and baldness in older men.
The V89L polymorphism in the 5-alpha-reductase
type 2 gene and risk of breast cancer.
Only 27 cases (6.6%) have sex reassignment, 15 from male to female (mainly cases of congenital adrenal hyperplasia, mixed gonadal dysgenesis, and 46,XX ovotesticular DSD) and 12 from female to male (mainly 5-alpha-reductase
type 2 deficiency).
1).[sup.4] The mainstay of medical treatments includes alpha-blockers, 5-alpha-reductase
inhibitors (5-ARIs), or a combination of the two.